By linking SPI pharmacology to WT1-associated microenvironmental features and tumor suppression, our findings provide a mechanistic rationale for repurposing Spironolactone as an immunomodulator to overcome therapeutic resistance in genitourinary oncology. This evidence concerns the gene WT1 and neoplasm.